Latest Microbiome Testing News

Page 1 of 1
Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.
Ada Torres
Ada Torres
28 Oct 2025
Microba Life Sciences reports strong Q4 FY25 growth driven by record microbiome test sales and clinician adoption in Australia and the UK, while advancing its therapeutics pipeline and targeting regional break-even in FY26.
Ada Torres
Ada Torres
22 July 2025
Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.
Ada Torres
Ada Torres
22 July 2025
Microba Life Sciences invites eligible shareholders to participate in a $2 million Share Purchase Plan at $0.09 per share, matching recent institutional pricing and including free attaching options. The capital raise aims to accelerate clinical adoption and push the company towards regional break-even.
Ada Torres
Ada Torres
27 June 2025
Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.
Ada Torres
Ada Torres
27 June 2025
Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.
Ada Torres
Ada Torres
23 June 2025
Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.
Ada Torres
Ada Torres
29 Jan 2025
Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.
Ada Torres
Ada Torres
29 Jan 2025